{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-082116","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2026-07-09T12:35:31+00:00","discovered_at":"2026-07-09T12:40:00.636482+00:00","generated_at":"2026-07-09T12:40:04.844908+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MetaVia completes dose titration in Phase 1 Part 3 of DA-1726 obesity trial; topline data on track for Q4 2026","bullets":["All active patients in Part 3A (48 mg) and Part 3B (64 mg) reached highest target doses after titration.","Prior Phase 1 MAD data showed 9.1% mean weight loss at 48 mg in 8 weeks, plus reductions in waist circumference and glycemic measures.","Part 3 enrolls ~40 obese subjects randomized 4:1 active:placebo across two 16-week titration cohorts.","Topline data from Part 3 remains on track for release in Q4 2026.","CEO cites favorable tolerability and efficient titration as potential competitive advantage over marketed obesity therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-082116","json":"https://secwatch.observer/filing/0001104659-26-082116.json","markdown":"https://secwatch.observer/filing/0001104659-26-082116.md","text":"https://secwatch.observer/filing/0001104659-26-082116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926082116/0001104659-26-082116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926082116/tm2620006d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-09T12:40:04.844908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}